118 related articles for article (PubMed ID: 30352944)
1. A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an
Kamath SD; Lin X; Kalyan A
Oncologist; 2019 Feb; 24(2):151-156. PubMed ID: 30352944
[TBL] [Abstract][Full Text] [Related]
2. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
3. IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.
Lee JH; Shin DH; Park WY; Shin N; Kim A; Lee HJ; Kim YK; Choi KU; Kim JY; Yang YI; Lee CH; Sol MY
World J Surg Oncol; 2017 Apr; 15(1):82. PubMed ID: 28403884
[TBL] [Abstract][Full Text] [Related]
4. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
6. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract][Full Text] [Related]
7. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
8. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.
Jabbar KJ; Luthra R; Patel KP; Singh RR; Goswami R; Aldape KD; Medeiros LJ; Routbort MJ
Am J Surg Pathol; 2015 Apr; 39(4):454-61. PubMed ID: 25634750
[TBL] [Abstract][Full Text] [Related]
9. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract.
Roos E; Soer EC; Klompmaker S; Meijer LL; Besselink MG; Giovannetti E; Heger M; Kazemier G; Klümpen HJ; Takkenberg RB; Wilmink H; Würdinger T; Dijk F; van Gulik TM; Verheij J; van de Vijver MJ
Crit Rev Oncol Hematol; 2019 Aug; 140():8-16. PubMed ID: 31158800
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
[TBL] [Abstract][Full Text] [Related]
11. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
12. Microfluidics for rapid detection of isocitrate dehydrogenase 1 mutation for intraoperative application.
Aibaidula A; Zhao W; Wu JS; Chen H; Shi ZF; Zheng LL; Mao Y; Zhou LF; Sui GD
J Neurosurg; 2016 Jun; 124(6):1611-8. PubMed ID: 26544771
[TBL] [Abstract][Full Text] [Related]
13. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D; Ferté C
Eur J Cancer; 2017 Aug; 81():161-173. PubMed ID: 28628842
[TBL] [Abstract][Full Text] [Related]
14. Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.
Bonfiglio S; Vanni I; Rossella V; Truini A; Lazarevic D; Dal Bello MG; Alama A; Mora M; Rijavec E; Genova C; Cittaro D; Grossi F; Coco S
BMC Cancer; 2016 Aug; 16(1):692. PubMed ID: 27578032
[TBL] [Abstract][Full Text] [Related]
15. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
16. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma.
Hartman DJ; Binion D; Regueiro M; Schraut W; Bahary N; Sun W; Nikiforova M; Pai RK
Am J Surg Pathol; 2014 Aug; 38(8):1147-56. PubMed ID: 25029120
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1
Acquaviva G; Visani M; de Biase D; Marucci G; Franceschi E; Tosoni A; Brandes AA; Rhoden KJ; Pession A; Tallini G
Sci Rep; 2018 Mar; 8(1):4459. PubMed ID: 29535392
[TBL] [Abstract][Full Text] [Related]
19. Treating Biliary Tract Cancers: New Targets and Therapies.
Ho J; Fiocco C; Spencer K
Drugs; 2022 Nov; 82(17):1629-1647. PubMed ID: 36441502
[TBL] [Abstract][Full Text] [Related]
20. Precision Medicine in Biliary Tract Cancer.
Scott AJ; Sharman R; Shroff RT
J Clin Oncol; 2022 Aug; 40(24):2716-2734. PubMed ID: 35839428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]